alendronate / Generic mfg. - LARVOL DELTA

Therapeutic liposomes synergize with active molecules to enhance targeted therapy. (PubMed, J Drug Target) - "Interestingly, liposomes containing essential PLs like phosphatidylserine with active molecules such as curcumin or alendronate could synergistically improve certain diseases like osteoporosis in experimental models. Accordingly, we aimed to highlight the unique advantages of various PLs or liposomes with an emphasis on their diverse therapeutic modalities and potentiation of liposomes in synergy with the cargos in experimental studies. These properties suggest a promising approach to enhance drug efficacy and mitigate the side effects through reduced drug usage in chronic diseases, however, their clinical translation requires further validation of safety and efficacy."

Journal • Review • Alzheimer's Disease • CNS Disorders • Osteoporosis • Rheumatology

Comparison between alendronate and denosumab in preventing bone loss and lowering fracture risk related to adjuvant endocrine therapy (AET) for breast cancer: real-world data from a Third Level Centre experience. (PubMed, Endocr Pract) - "Treatment with denosumab during AET improves BMD and TBS more than alendronate and is associated with greater reduction of major fractures in postmenopausal patients affected by osteopenia or osteoporosis."

Journal • Real-world evidence • Breast Cancer • Musculoskeletal Diseases • Oncology • Rheumatology • Solid Tumor

Tough-engineered multifunctional alendronate anchoring of dysprosium impregnated luminescent polyvinyl alcohol-chitosan composite hydrogels. (PubMed, Biomater Adv) - "The biocompatibility tests revealed ∼90 % cell viability and improved osteogenic differentiation such as ALP and calcium nodules. Moreover, the CAM assay revealed the ability of hydrogel to accelerate the vessel formation through their integration with the branching points."

Journal

The Role of Full Femur Imaging for Early Detection of Incomplete Atypical Femur Fractures (ENDO 2025) - "Introduction: Atypical femur fractures (AFFs) are a rare but serious complication linked to prolonged use of bisphosphonates and denosumab...After seven years on alendronate, she sustained a complete right AFF requiring intramedullary nailing...Incorporating FFI into routine osteoporosis care is not routinely implemented and may highlight a gap in current practice. This case emphasizes the need for clear guidelines on screening for AFFs and the potential role of FFI in personalized imaging protocols to enhance patient care."

Diabetes • Dyslipidemia • Endocrine Disorders • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Type 2 Diabetes Mellitus

Challenges in Endocrine Function Testing During Clinical Cancer Drug Trials: False Positives Due to Heterophilic Antibodies (ENDO 2025) - "She was referred to the Endocrinology Department for osteoporosis management, and after evaluation, she was treated with Denosumab and cholecalciferol...Two months after switching to alendronate, PTH was measured at 1171 pg/mL...Following the initiation of osteoporosis treatment, the patient participated in a clinical trial to assess the safety and efficacy of Oregovomab in combination with Paclitaxel, Carboplatin, and Bevacizumab... Heterophilic antibodies have been recognized for a long time, but caution is needed as mouse-derived antibodies are still used in early-stage research. These antibodies can cross-react with non-homologous antigens, interfere with immunoassays, and lead to inaccurate test results."

Clinical • Endocrine Disorders • Oncology • Ovarian Cancer • Pituitary Gland Carcinoma • Rheumatology • Solid Tumor

Awareness and Attitude Towards MRONJ Among Physicians Prescribing Antiresorptive Drugs: A Cross-Sectional Study. (PubMed, BMC Oral Health) - "To enhance awareness of MRONJ, a multidisciplinary approach should be adopted between medical and dental disciplines, and a well-coordinated consultation system should be established. This will ensure that patients undergo dental examinations and complete necessary interventional dental procedures before commencing antiresorptive drug therapy. Furthermore, implementing educational strategies such as academic publications, training seminars, and symposia is of great importance to increase the level of awareness on this issue."

Journal • Observational data • Gynecology • Musculoskeletal Diseases • Obstetrics • Oncology • Orthopedics • Osteoporosis • Rheumatology

The efficacy and safety of denosumab, risedronate, alendronate and teriparatide to treat male osteoporosis: a systematic review and bayesian network meta-analysis. (PubMed, Front Endocrinol (Lausanne)) - "Treatment choices should weigh site-specific needs against risk tolerance. https://www.crd.york.ac.uk/prospero, identifier CRD42024599021."

Clinical • Journal • Retrospective data • Review • Osteoporosis • Rheumatology

Introducing equivalent and threshold doses in the assessment of medication-related osteonecrosis of the jaw risk: insights from a descriptive study in Iran. (PubMed, Support Care Cancer) - "This study offers critical insights into MRONJ risk stratification, highlighting the cumulative impact of medication dose alongside clinical risk factors. The introduction of ED and TD represents a transformative advancement in MRONJ risk prediction, enabling precise prevention strategies and guiding clinical management toward standardized care protocols."

Journal • Oncology • Rheumatology

Treatment-Related Changes In Total Hip Bone Mineral Density And Fracture Risk Reduction For Trials With Active Control And Sequential Therapy: The Fnih-Asbmr-Sabre Project (ENDO 2025) - "This analysis aimed to determine if these associations and STEs apply to trials using active control or sequential therapies.Material and methods We used individual patient data from 19 trials: 16 randomized, placebo-controlled trials (14 anti-resorptive, 1 teriparatide, 1 odanacatib), and 3 trials with active control or sequential therapy (1 abaloparatide/alendronate and 2 romosozumab/alendronate or denosumab).For each trial, we calculated the treatment-related difference in mean percentage change in THBMD at 24 months and the risk reductions for the entire follow-up period. In trials with active control or sequential therapy, the increase in THBMD was greater than STE and associated with a significant decrease in fracture risk: the increase in THBMD was 4.57%; 3.69% and 3.12%respectively for romosozumab/denosumab, romosozumab/alendronate and abaloparatide/alendronate trials, and the STE was 1.43% for vertebral and 2.04% for all clinical fractures. Conclusion Our..."

Late-breaking abstract • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Iodine-Induced Thyrotoxicosis Leading to Severe Osteoporosis: A Case Report (ENDO 2025) - "Common sources include iodized salt, amiodarone, and seaweed-based supplements such as kelp. We report a case of iodine-induced thyrotoxicosis secondary to kelp consumption, resulting in severe osteoporosis, emphasizing the importance of dietary awareness in thyroid management.CaseA 58-year-old woman with osteoporosis, low BMI, and premature ovarian insufficiency (POI) was evaluated for worsening bone density despite prior treatment with alendronate...She was advised to avoid excessive iodine and was treated with prednisone. She also started denosumab but was lost to follow-up...Kelp and similar supplements can exceed the recommended iodine intake of 1,100 mcg/day, necessitating dietary education.This case highlights the difficulty of managing iodine-induced thyrotoxicosis, especially when unrecognized supplement intake is involved. Comprehensive care should include dietary counseling and, when needed, psychiatric evaluation to address behavioral patterns contributing to..."

Case report • Clinical • Cardiovascular • Endocrine Disorders • Movement Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Psychiatry • Rheumatology • Women's Health

Comparative Effects of Denosumab and Alendronate on Incidence of Type 2 Diabetes Mellitus in Patients with Osteoporosis: A Nationwide Study (ENDO 2025) - "These results suggest that both medications have comparable effects on T2D risk in osteoporosis patients. Given the observational nature of the study and potential residual confounding factors, further prospective research with longer follow-up and detailed clinical data is warranted to clarify the long-term metabolic effects of antiosteoporotic agents."

Clinical • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Renal Disease • Rheumatology • Type 2 Diabetes Mellitus

A comprehensive update on the cost-effectiveness of 10-year denosumab vs alendronate in postmenopausal women with osteoporosis in the United States. (PubMed, Arch Osteoporos) - "Ten-year denosumab treatment would be cost-effective compared with 5 years of alendronate, followed by a 2-year drug holiday and 3 years of alendronate at the threshold of $150,000. Cost-effectiveness was demonstrated across most scenarios with robust PSA results."

Clinical • HEOR • Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

From Bone Density to Bone Death: Osteonecrosis of the Jaw in a Patient with Minimal Risk Factors (ENDO 2025) - "BRONJ occurs in 0.01%-0.06% of OP patients and up to 8% of cancer patients receiving higher and more frequent doses of antiresorptive medications or jaw radiation.Here we present a case of a 70-year-old female with a history of OP, who developed osteonecrosis of the jaw after 5 years of alendronate use with limited risk factors. It emphasizes the importance of careful monitoring during BP therapy, and also raises the concern about treatment options for managing worsening OP in patients with BRONJ. Non-BP therapies, such as denosumab or teriparatide, could be considered to prevent further bone loss and fractures, but also carries the risk of ONJ, although data is limited."

Clinical • Endocrine Disorders • Musculoskeletal Diseases • Oncology • Pain • Rheumatology

Effects of bisphosphonates & denosumab on bone mineral density in patients with osteoporosis - A study from central India. (ENDO 2025) - "Three groups of treatment alendronate- N=13, Zoledronic acid- N=39 & denosumab- N=11 allocated. For better understanding more sample size & long-term outcome studies are required. Treating such patients had resulted rewarding results."

Clinical • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Optimal Timing of Denosumab with Parathyroidectomy in the Setting of Primary Hyperparathyroidism​ (ENDO 2025) - "She had difficulty controlling her symptoms with steroid-sparing agents, needing 20-60mg of daily prednisone for 2 years. She started alendronate, calcium citrate, and high dose ergocalciferol prior to presenting to endocrinology... Parathyroidectomy was scheduled in proximity to the next denosumab dose since timing is important due to rebound resorption phenomenon and increased risk of vertebral fractures after delayed or missed denosumab doses. However, peri-procedural hypoparathyroidism and severe hypocalcemia can result if potent anti-resorptive therapy prevents liberation of calcium from bone. Considering this, denosumab was given 8 weeks after parathyroidectomy."

Cardiovascular • Dermatology • Endocrine Disorders • Grave’s Disease • Hypoparathyroidism • Immunology • Inflammatory Arthritis • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Psoriasis • Rheumatology • Secondary Hyperparathyroidism

Asymptomatic Paget's Disease Of Bone Resulting In A Low Trauma Subtrochanteric Fracture With Normal Markers Of Bone Turnover (ENDO 2025) - "The patient was discharged with a plan for follow up on alendronate 40 mg daily and ergocalciferol 50,000 international units weekly... This is a unique case of Paget's disease of a major weight bearing site following fracture of the left subtrochanteric area and surgery. While it is expected that this patient would have manifested elevated markers of bone turnover in the setting of advanced Paget's disease, this case is unique is that ALP, CTx, and BALP were not significantly elevated despite a fracture and surgical manipulation of a major weight bearing site. Reasons for this may include decreased bone turnover and metabolic activity seen in the late sclerotic phase of PDB, fracture occurring primarily from mechanical weakness in advanced PDB due to a disorganized and sclerotic bone architecture, and laboratory limitations of detecting elevated markers in post-fracture state."

Late-breaking abstract • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rare Diseases

"Strengthening Bones, Supporting Lives: Romosozumab in Osteoporosis Management for Marfan Syndrome" (ENDO 2025) - "For osteoporosis, patient was previously on alendronate followed by raloxifene with a combined treatment course of approximately 15 years. Given the severity of her osteoporosis, our patient completed a 12-month course of therapy without any significant side effects and was found to have clinically significant improvement in her axial bone mineral density.CONCLUSIONTo our knowledge, there are no case reports on use of Romosozumab in the MFS population with osteoporosis. This case report highlights this therapy as a possible effective therapeutic intervention but also recognizes the need for ongoing research to establish standard and effective treatment guidelines for management of osteoporosis in MFS."

Endocrine Disorders • Genetic Disorders • Grave’s Disease • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • FBN1

A Rare Case of Nail Patella Syndrome and Osteoporosis (ENDO 2025) - "Alendronate was prescribed from 2005 to 2012...Her labs upon consultation in 2024 were notable for serum calcium 9.39 mg/dL (8.6-10.3 mg/dL), 25 hydroxy vitamin D level 70 ng/mL (30-100 ng/mL), and C-telopeptide level 112 pg/mL. Due to her low C-telopeptide and improvement in her DXA a bisphosphonate holiday was reinitiated in 2024.Clinical lessons: Patients with nail patella syndrome have a higher risk of early osteoporosis and should be monitored closely to evaluate for early intervention."

Clinical • Allergic Rhinitis • Dermatology • Endocrine Disorders • Gastroesophageal Reflux Disease • Immunology • Inflammation • Musculoskeletal Diseases • Ophthalmology • Orthopedics • Osteoporosis • Pulmonary Disease • Renal Disease • Rheumatology • Urology

Delayed Diagnosis of Hypophosphatasia in a 91-year-old: An Opportunity to Improve Screening (ENDO 2025) - "His low BMD had been treated with six 5-mg doses of zoledronate (ZOL) from 2010 to 2023 and alendronate prior to 2010...Additional ZOL was held and he was evaluated for asfotase alfa... HPP may be overlooked particularly in older adults with low BMD and low ALP on long-term bisphosphonate therapy as illustrated in this case. Our patient's low ALP level was presumed secondary to longstanding suppression of bone turnover from many years of bisphosphonate exposure. Although bisphosphonates can increase risk of atypical femur fractures in HPP, our patient had no such complications."

CNS Disorders • Depression • Musculoskeletal Diseases • Orthopedics • Otorhinolaryngology • Psychiatry • Rheumatology • ALPL

The Hidden Fallout of Childbirth: A Missed Sheehan's Syndrome Leading to Multiple Organ Dysfunction (ENDO 2025) - "Echocardiography revealed dilated cardiomyopathy (LVEF 30%), necessitating digoxin and diuretics...Endocrine replacement therapy was initiated with IV hydrocortisone, followed by oral prednisolone (5 mg and 2.5 mg) and thyroxine (50 to 100 mcg). Given her osteoporosis (DEXA T-score -3.0), alendronate, vitamin D, and calcium were added... Sheehan's syndrome can take years or decades to manifest, requiring a high index of suspicion in women with a history of agalactia, hypomenorrhea, or amenorrhea. Detailed obstetric history, attention to psychosomatic symptoms, and comprehensive endocrine evaluation, beyond TSH levels, are crucial for diagnosis. Women with a history of PPH should be closely monitored for hypopituitarism to prevent long-term complications."

Clinical • Anemia • Cardiomyopathy • Cardiovascular • Endocrine Disorders • Heart Failure • Hematological Disorders • Hypotension • Infectious Disease • Obstetrics • Osteoporosis • Pain • Postpartum Hemorrhage • Pulmonary Disease • Respiratory Diseases • Rheumatology • Severe Hypoglycemia • Tuberculosis • Women's Health

Bisphosphonate Related Avascular Necrosis of the Humerus: A Case Report (ENDO 2025) - "At the February 2022 visit, patient was placed on oral alendronate 70 mg once weekly and was discharged to her PCP for monitoring... This case illustrates a rare but important complication of bisphosphonate therapy. Early recognition and discontinuation of bisphosphonates, followed by appropriate treatment such as teriparatide improves outcomes in affected patients. Further research is needed to better understand the mechanisms of bisphosphonates as the etiology of AVN and to identify patients at greatest risk for this complication."

Case report • Clinical • Cognitive Disorders • Dry Eye Disease • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Ophthalmology • Orthopedics • Osteoporosis • Pain • Rheumatology • Sjogren's Syndrome • Xerostomia

Significant One-Year Bone Mineral Density Gains Following a Single Dose of Romosozumab: Insights from Two Case Studies (ENDO 2025) - "Here we report the one-year bone mineral density (BMD) gains following one dose of Romosozumab in two anabolic-naive patients.Case PresentationPatient 1 is a 76-year-old female diagnosed with osteoporosis in August 2023 and treated with Alendronate 70 mg daily for four months, followed by one dose of Romosozumab in April 2024, with no subsequent treatment. Between August 2023 and September 2024, she had statistically significant improvements in BMD at the lumbar spine (13.9%), right femur (7.9%), and left femur (9.6%).Patient 2 is a 67 year old female with osteoporosis treated with one dose of Romosozumab in January 2024 followed by one dose of Zoledronic acid in February 2024...Our patients' one-year BMD improvement after one dose of Romosozumab was similar to the one-year BMD improvement of clinical trial patients after twelve doses of Romosozumab. 2.There is a need for further research to determine whether shorter treatment courses could reduce fractures..."

Case study • Clinical • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Osteoclast-secreted galectin-3 promotes articular cartilage degeneration in OVX rat via LRP1/beta-catenin axis. (PubMed, Osteoarthritis Cartilage) - "Osteoclast-secreted Gal-3 promotes articular cartilage degeneration in OVX rats by combining with LRP1 and activating β-catenin pathway in chondrocyte. Targeting Gal-3 could be a promising therapeutic strategy for estrogen deficiency-associated OA."

Journal • Preclinical • Immunology • Metabolic Disorders • Osteoarthritis • Osteoporosis • Pain • Rheumatology • ACAN • ADAMTS5 • COL2A1 • CTNNB1 • LGALS3 • LRP1 • MMP13

A novel triterpenoid saponin from Pimpinella candolleana alleviates postmenopausal osteoporosis via P38/JNK MAPK-mediated osteogenesis. (PubMed, Phytomedicine) - "CP-1 is a promising natural candidate for PMOP therapy by enhancing osteogenesis via MAPK activation and bone metabolism regulation."

Journal • Osteoporosis • Rheumatology

BEACON: Bone, Exercise, Alendronate, and Caloric Restriction (clinicaltrials.gov) - P4 | N=900 | Recruiting | Sponsor: Wake Forest University Health Sciences | Phase classification: P3 ➔ P4

Phase classification • Osteoporosis